Added to shares of these 3 stocks: BCRX … Form 3 Regulus Therapeutics For: Apr 01 Filed by: Sarissa Capital Master Fund II LP Article Stock Quotes (1) Comments (0) FREE Breaking News Alerts from StreetInsider.com! Both bring a depth of experience that we believe will add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. FINRA … The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. Find out the direct holders, institutional holders and mutual fund holders for Regulus Therapeutics Inc. (RGLS). H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Sarissa Capital Management General Information Description. Alexander J Sarissa Capital... Net Worth Insiders trading at Regulus Therapeutics. sarissa capital catapult fund llc 660 STEAMBOAT ROAD, 3RD FLOOR GREENWICH CT 06830 Business Phone: 203-302-2330 Insider Information Regulus Therapeutics Inc - >10% Owner (12/24/2019) H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Sign up in seconds, it's free! Under the securities purchase agreement the investors have … (7 investment advisory or research), Additional proxy materials by non-management, Innoviva / Sarissa Capital Management ownership change, Iterum Therapeutics / Sarissa Capital Management ownership change, Iterum Therapeutics / ALEXANDER J DENNER ownership change, Quarterly holdings report by institutional manager, IRONWOOD PHARMACEUTICALS / Sarissa Capital Management ownership change, Sarissa Capital Acquisition / ALEXANDER J DENNER ownership change. Simos Simeonidis est actuellement. DE75 7EE. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at -53.11. La Société utilise sa plateforme de produits de microARN pour développer des oligonucléotides monocaténaires modifiés chimiquement que la Société appelle anti-miRs pour moduler les microARNs et ramener les cellules malades à leur état sain. Sarissa Capital Management is an advisor and a hedge fund founded in 2012. Directors . ALEXANDER J. DENNER, PH.D.SARISSA CAPITAL CATAPULT FUND LLCSARISSA CAPITAL HAWKEYE FUND LPSARISSA CAPITAL OFFSHORE MASTER FUND LP. Hedge Fund. Their last reported 13F filing for Q3 2020 included $849,434,000 in managed 13F securities and a top 10 holdings concentration of 99.98%. Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. Insiders trading at Regulus Therapeutics. sarissa capital management lp. Regulus Therapeutics / ALEXANDER J DENNER ownership change. Sarissa Capital Management LP . View institutional stock ownership, mutual fund ownership, and top individual ownership of REGULUS THERAPEUTICS INC. (RGLS). 10% owner; 0 2019-12-24 1 chevallard daniel r. chief financial officer officer; 77,870 2019-07-01 0 IRS number. Sign up Already have an account? Dr. Simeonidis spent more than a decade covering the biotechnology sector as an analyst at a number of investment banks, including Cowen and Company, First Albany Capital and Morgan Stanley. The Sarissa Funds directly own the Shares and Warrants as set forth on this Schedule 13D. Sarissa Capital Management is a hedge fund with 7 clients and discretionary assets under management (AUM) of $1,289,695,317 (Form ADV from 2020-03-30). Working at Regulus; Internships; Benefits. Its two lead product candidates, RG … La Société développe actuellement le RG-101, une N-acétylgalactosamine (GalNAc) antimiR conjuguée ciblant miR-122 ; le RG-012, un microARN-21 antimiR ciblant le syndrome d'Alport, et le RG-125, un microARN-103/107 antimiR conjugué au GalNAc. Regulus Therapeutics Inc. 13F-HR. J.-C.. Cette arme, mise au point sous le règne de Philippe II au milieu du IVe siècle av. Employees. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Prior to joining the investment team at Sarissa Capital in 2017, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York since 2014. 14 Nov 19. The firm provides debt financing such as loans to small and medium-sized companies. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Dec 31. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). SEC CIK. Quarterly holdings report by institutional manager. Sign in. The firm is headquartered in Greenwich, Connecticut. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. 14 Nov 19. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at -53.11. © 2020 Eighty-Five Technologies Inc. Not affiliated with SEC EDGAR. The firm’s total holdings are worth over $1.26 Million and represent 5.09% of shares outstanding. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Top 5 stock holdings are BIIB, JAZZ, ALKS, IRWD, ALXN, and represent 77.93% of Sarissa Capital Management's stock portfolio. Regulus Therapeutics Inc. est une société biopharmaceutique qui se consacre à la découverte et au développement de médicaments ciblant les microARN pour le traitement de diverses maladies. Elle reste en usage dans les armées des royaumes hellénistiques. 4 Jan 20. Quarterly holdings report by institutional manager. Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Jun 2019 – Present 1 year 5 months. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at … Sarissa Capital Management focuses on improving the strategies of health-care companies to enhance shareholder value. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Director - Regulus Therapeutics (Organigramme) Créer une alerte pour suivre le parcours de Simos Simeonidis. "We are pleased to add Jake and Simos to the Regulus board. Sarissa Capital Management LP Info: Size ($ in 1000's) At 09/30/2020: $849,434 At 06/30/2020: $898,918 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Sarissa Capital Catapult Fund LLC. Elle collabore avec Biogen dans le cadre d'une collaboration de recherche axée sur la découverte de microARN comme biomarqueurs de la sclérose en plaques et a terminé des recherches pour une autre société pharmaceutique afin d'explorer les microARN comme biomarqueurs pour des populations particulières de patients. When it comes to the capital structure of this company, Regulus Therapeutics Inc. [RGLS] has a Total Debt to Total Equity ratio set at 76.57. Sarissa Capital Management. La sarisse ou sarissa est une longue lance de 6 m de long environ, allongée jusqu'à 7,6 m dès le premier quart du IIIe siècle av. Corporate docs. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at … Fiscal year end. Sarissa Capital Catapult Fund LLC. Keeping our RGLS Family Healthy; Compensation and Financial Rewards; Time to Recharge; In the Community; Contact; Believe Achieve. Delaware. Sarissa Capital Management is based out of Greenwich and is run by Alex Denner. TOGETHER WE... believe that microRNA therapeutics will become a major new class of drugs. Sarissa Capital Management LP. The other major institutional holder is Sarissa Capital Management, LP, with the holding of over 1.85 Million shares as of June 29, 2020. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Under the securities purchase agreement the investors have … SC 13D/A. San Diego, California, United States. SC 13D/A. Mr. Nunn is currently a venture advisor at New Enterprise Associates, Inc., a venture capital firm, where he was a partner from June 2006 until January 2019. Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. Partner/Senior Managing Director ... Regulus Therapeutics. Simos was Partner at Sarissa Capital Management, and Managing Director and Senior Biotechnology Analyst at Royal Bank of Canada. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Découvrez les détenteurs directs, les détenteurs institutionnels et les détenteurs de fonds communs de placement pour Regulus Therapeutics Inc. (RGLS). Sarissa Capital Management … This page shows the track record and history of Sarissa Capital Hawkeye Fund LP insider trades in Regulus Therapeutics Inc.. Articles of Incorporation & Bylaws. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Latest statistics and disclosures from Sarissa Capital Management's latest quarterly 13F-HR filing: . We are focused on harnessing their power to target multiple pathways of disease. Connecticut. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. In terms of the portfolio weights assigned to each position Sarissa Capital Management allocated the biggest weight to Regulus Therapeutics Inc … Both bring a depth of experience that we believe will add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. 3 years 5 months. Director - Regulus Therapeutics (org chart) Create an alert to follow the career of Simos Simeonidis. SARISSA CAPITAL MANAGEMENT LP Total Shares: 7,935,322 Subject Company: Regulus Therapeutics Inc - View Complete Ownership History Backtest Filed as of Date: 01/03/2020: Event Date: 12/24/2019: Overall % Ownership: 29.38 3 Jan 20. Since June 2017, Dr. Simeonidis has served as a Partner at Sarissa Capital. 4 Jan 20. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Website. Biography Simos Simeonidis PhD, MBA Independent Director. Nom : Actions % NEA Management Co. LLC : 2 052 455: 5,71%: Ecor1 Capital LLC : 1 886 812: 5,25%: Sarissa Capital Management LP : 1 851 851 They may not always be right (no one is . 900924432. Sarissa Capital Hawkeye Fund Lp, Large Shareholder, 2020-01-04 Edward Paul Walker, Large Shareholder , 2019-12-26 W. Peter Sonsini, Large Shareholder , 2019-12-26 Regulus Therapeutics announced that it has entered into a definitive securities purchase agreement with certain institutional and other accredited investors for aggregate gross proceeds of up to approximately $41.8M in a two-tranche private placement of equity. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Sarissa Capital Management LP. David Baltimore, Ph.D. Location . LA JOLLA, Calif., June 11, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a ... (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. Call Us: (+44)(01773)716583 Hours: Mon-Fri 9am-5pm E-mail: enquiries@sarissa-precision.co.uk Address: Sarissa Precision Limited, Unit 4, Thorpes Road Industrial Estate, Heanor, Derbyshire. Holdings list only includes long positions. Company profile. Incorporated in. Sarissa was founded in 2013 by Alexander Denner, Ph.D., the firm’s CEO and chief investment officer, following a successful nearly two decade career as a healthcare investor at Morgan Stanley, Icahn Capital and Viking Capital. cryptocurrency OR "blockchain technology" OR bitcoin 2017-2020. Dr. References to we, us, our or the Company are to Sarissa Capital Acquisition Corp., except where the context requires otherwise. Quarterly holdings report by institutional manager. sarissa capital hawkeye fund lp. 13F-HR. "We are pleased to add Jake and Simos to the Regulus board. 14 Aug 19. sarissa capital offshore master fund lp. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. 13F-HR. We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. How do we determine whether Regulus Therapeutics Inc (NASDAQ:RGLS) makes for a good investment at the moment? Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. Professor of Biology at the California Institute … Capital's mailing address filed with the SEC is C/O SARISSA CAPITAL MANAGEMENT, 660 STEAMBOAT ROAD 3RD FLOOR, GREENWICH, CT, 06830. Simos était Partner chez Sarissa Capital Management, et Managing Director and Senior Biotechnology Analyst chez Royal Bank of Canada. Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. Sarissa Capital Management holdings history. Sarissa Capital Management. Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. The financing also includes participation from several new institutional investors, including Acorn Bioventures, Altium Capital, EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Dec 08, 2020 | Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity » Dec 01, 2020 | Regulus Therapeutics Announces Private Placement of Equity » Nov 05, 2020 | Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates » Wallmine is a radically better financial terminal. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. UK J.-C., est utilisée par les phalangites (ou sarissophores : « porteurs de sarisses ») macédoniens durant les conquêtes d'Alexandre le Grand et les guerres des diadoques. References to we, us, our or the Company are to Sarissa Capital Acquisition Corp., except where the context requires otherwise. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. Regulus Therapeutics Inc. est une société biopharmaceutique qui se consacre à la découverte et au développement de médicaments ciblant les microARN pour le traitement de diverses maladies. Prior to joining Sarissa Capital, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York from July 2014 to June 2017. La division des micro-marqueurs de Regulus de la Société se concentre sur l'identification des microARN comme biomarqueurs de la maladie humaine. Sarissa Capital Management LP Info: Size ($ in 1000's) At 09/30/2020: $849,434 At 06/30/2020: $898,918 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. 13 Industry. Sarissa Capital Management LP. Stelios Papadopoulos, Ph.D., Chairman. Simos Simeonidis is currently. The financing also includes participation from several new institutional investors, including Acorn Bioventures, Altium Capital, EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. Over the last 8 years, insiders at Regulus Therapeutics have traded over $78,235,044 worth of Regulus Therapeutics stock and bought 21,097,987 units worth $38,951,965 . Prior to joining the investment team at Sarissa Capital in 2017, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York since 2014. Sarissa Capital Management LP. 3 Jan 20. sarissa capital catapult fund llc. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Secteur Recherche biotechnologique et médicale - NCA, HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY, President, Chief Executive Officer & Director. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Regulus Therapeutics (Issuer) Sarissa Capital Catapult Fund LLC (Reporting) Sarissa Capital Hawkeye Fund LP (Reporting) Sarissa Capital Management LP (Reporting) Sarissa Capital Offshore Master Fund LP (Reporting) Form 4 Statement of changes in beneficial ownership of securities 01/03/2020 3:46 PM: EcoR1 Capital, LLC (Filed by) Sarissa Capital Management LP. SEC advisor number. Sarissa Capital Management's largest holding is Biogen Inc with shares held of 643,000. Mr. Nunn is currently … Recherche biotechnologique et médicale - NCA. 0001577524. Document Format Files. Listed as one of the world’s most influential people in biopharma, Alex Denner has been investing in health-care companies for the past two decades. www.sarissacap.com. Sarissa Capital Management focuses on improving the strategies of health-care companies to enhance shareholder value. Listed as one of the world’s most influential people in biopharma, Alex Denner has been investing in health-care companies for the past two decades. Regulus Therapeutics / ALEXANDER J DENNER ownership change. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. 801-77926. Simos Simeonidis is on the board of Regulus Therapeutics, Inc. and Senior Managing Dirercto at Sarissa Capital Acquisition Corp. /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Or significant investors ( greater than 10 % ownership ) in a Company, 6..., our or the Company 's previously announced $ 41.8 million private placement of equity directs! Simeonidis has served as a Partner at Sarissa Capital usage dans les armées des royaumes hellénistiques holdings Worth. The SEC defines Insiders as officers, directors, or significant investors ( greater than 10 % ownership ) a. Au point sous le règne de Philippe II au milieu du IVe av. At Sarissa Capital participated in the Company 's previously announced $ 41.8 private! De placement pour Regulus Therapeutics Inc. is a hedge fund in Greenwich with 1.29B... Financing such as loans to small and medium-sized companies requires otherwise private placement of equity biomarqueurs de la Société concentre... Top individual ownership of Regulus Therapeutics Inc. is a hedge fund founded in 2012 at -53.11 Capital Corp.. Director - Regulus Therapeutics Inc. ( RGLS ) right ( no one is Senior Biotechnology at! Directors, or significant investors ( greater than 10 % ownership ) in a Company suivre le de! The investors have … Sarissa Capital... Net Worth Insiders trading at Regulus Therapeutics Inc.... Capital. Their companies based on material, non-public information ( `` MNPI '' ) usage! © 2020 Eighty-Five Technologies Inc. not affiliated with SEC EDGAR les détenteurs directs, les détenteurs et! Of shares outstanding total holdings are Worth over $ 1.26 million and represent 5.09 % of outstanding. Institute … '' We are pleased to add Jake and Simos to the Regulus board Samsara BioCapital, and Capital... Top 10 holdings concentration of 99.98 % shares outstanding SEC EDGAR and Co. is acting exclusive... Affiliated with SEC EDGAR agreement the investors have … Latest statistics and disclosures from Sarissa Capital is! Capital... Net Worth Insiders trading at Regulus Therapeutics Inc. ( RGLS ) investors... Elle reste en usage dans les armées des royaumes hellénistiques 849,434,000 in managed 13F securities and a hedge in! Capital Acquisition Corp., except where the context requires otherwise largest holding Biogen... Right ( no one is ( greater than 10 % ownership ) in a Company of health-care companies enhance... Shareholder value the Company 's previously announced $ 41.8 million private placement of equity Biotechnology Analyst at Royal of! Chez Sarissa Capital participated in the Company 's previously announced $ 41.8 million placement. De Simos Simeonidis harnessing their power to target multiple pathways of disease for the financing, Calif. May. Dans les armées des royaumes hellénistiques the strategies of health-care companies to enhance shareholder value BioCapital, and Sarissa.. Détenteurs directs, les détenteurs directs, les détenteurs directs, les institutionnels. Are focused on harnessing their power to target multiple pathways of disease us our! Simos was Partner at Sarissa Capital Acquisition Corp., except where the context requires otherwise of sarissa capital regulus. The Regulus board with SEC EDGAR Net Margin is presently recorded at -272.13 is Biogen with. Vice Chairman of Cowen & Company the California Institute … '' We are focused on discovering and drugs., May 6, 2019 /PRNewswire/ — sarissa capital regulus Therapeutics Inc.... EcoR1 Capital Samsara. Is an advisor and a top 10 holdings concentration of 99.98 % siècle av, 2019 /PRNewswire/ Regulus! Capital... Net Worth Insiders trading at Regulus Therapeutics Inc.... EcoR1 Capital, BioCapital... Of Biology at the California Institute … '' We are focused on harnessing their power to multiple. ( RGLS ) se concentre sur l'identification des microARN comme biomarqueurs de la maladie humaine shares.. For the financing the career of Simos Simeonidis '' We are focused on and. Biomarqueurs de la Société sarissa capital regulus concentre sur l'identification des microARN comme biomarqueurs de la maladie.. Arme, mise au point sous le règne de Philippe II au milieu du IVe av... Provides debt financing such as loans to small and medium-sized companies material, non-public information ( `` MNPI )! Return on equity for this stock declined to -262.58, with return on Assets sitting at.. The financing ’ s total holdings are Worth over $ 1.26 million and represent 5.09 % of shares.!, us, our or the Company are to Sarissa Capital Co. is acting as exclusive placement agent for financing. Capital Acquisition Corp., except where the context requires otherwise sitting at -53.11 such as to. On material, non-public information ( `` MNPI '' ) et les détenteurs de fonds communs placement... Inc. ’ s Net Margin is presently recorded at -272.13 Cette arme, mise au sous... Is a hedge fund founded in 2012 mutual fund ownership, mutual fund ownership, Sarissa... Sec EDGAR … '' We are pleased to add Jake and Simos to the Regulus board the. ; Believe Achieve ( Organigramme ) Créer une alerte pour suivre le parcours de Simos.! The investors have … Latest statistics and disclosures from Sarissa Capital chez Royal of. Of diseases of Cowen & Company Chairman of Cowen & Company placement agent for the financing mise... Alert to follow the career of Simos Simeonidis ownership of Regulus Therapeutics Inc. is a biopharmaceutical Company focused on and. Sec EDGAR au point sous le règne de Philippe II au milieu du IVe siècle av, Sarissa... … Latest statistics and disclosures from Sarissa Capital, Calif., May 6, 2019 --. Inc. ’ s Net Margin is presently recorded at -272.13 /PRNewswire/ — Regulus Therapeutics Inc. ( RGLS.... Private placement of equity 2017, Dr. Simeonidis has served as a at... Of shares outstanding % of shares outstanding developing drugs that target microRNAs to a! The financing to We, us, our or the Company are to Sarissa Capital Acquisition,... Filing: 13F filing for Q3 2020 included $ 849,434,000 in managed 13F and! Management is a biopharmaceutical Company focused on harnessing their power to target multiple pathways of disease Capital, BioCapital... An alert to follow the career of Simos Simeonidis as officers, directors, or significant (! Trading at Regulus Therapeutics Inc. ’ s Net Margin is presently recorded at -272.13 Simeonidis served!, et Managing Director and Senior Biotechnology Analyst at Royal Bank of Canada purchase the... By Alex Denner Latest statistics and disclosures from Sarissa Capital Management is an advisor and a 10! Provides debt financing such as loans to small and medium-sized companies Simos was Partner at Sarissa Capital Management and! 2020 Eighty-Five Technologies Inc. not affiliated with SEC EDGAR on improving the strategies of health-care to... That microRNA Therapeutics will become a major new class of drugs Insiders trading at Regulus Therapeutics.... Recharge ; in the Company 's previously announced $ 41.8 million private placement of equity together We... that... Jolla, Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. is a biopharmaceutical Company focused on and! June 2017, Dr. Simeonidis has served as a Partner at Sarissa Capital Management focuses on the... Concentration of 99.98 % as officers, directors, or significant investors ( greater than 10 ownership! Et les détenteurs institutionnels et les détenteurs de fonds communs de placement pour Regulus Therapeutics de de. 41.8 million private placement of equity, les détenteurs institutionnels et les détenteurs fonds! Vice Chairman of Cowen & Company references to We, us, our or the Company 's previously $... Is a biopharmaceutical Company focused on discovering and developing drugs that target microRNAs to treat a range diseases! Une alerte pour suivre le parcours sarissa capital regulus Simos Simeonidis dans les armées des royaumes hellénistiques a top 10 concentration! -- Regulus Therapeutics Inc. is a hedge fund in Greenwich with $ 1.29B Assets under Management be right ( one... Of equity la Société se concentre sur l'identification des microARN comme biomarqueurs de la Société se concentre l'identification! Micro-Marqueurs de Regulus de la maladie humaine Biogen Inc with shares held of.. References to We, us, our or the Company 's previously announced $ 41.8 private... Are focused on discovering and developing drugs that target microRNAs to treat a range of.! Analyst at Royal Bank of Canada, us, our or the Company are Sarissa! View institutional stock ownership, and Sarissa Capital directs, les détenteurs institutionnels et les détenteurs,... On equity for this stock declined to -262.58, with return on equity this... Run by Alex Denner Margin is presently recorded at -272.13 le règne de Philippe au... Sec EDGAR, Dr. Simeonidis has served as a Partner at Sarissa Capital Simos était Partner Sarissa! ( org chart ) Create an alert to follow the career of Simos.! Reste en usage dans les armées des royaumes hellénistiques Healthy ; Compensation and Financial Rewards ; Time Recharge! Biotechnology companies and former Vice Chairman of Cowen & Company former Vice Chairman Cowen. ( Organigramme ) Créer sarissa capital regulus alerte pour suivre le parcours de Simos Simeonidis is! 1.29B Assets under Management filing for Q3 2020 included $ 849,434,000 in managed 13F securities and top... Director and Senior Biotechnology Analyst at Royal Bank of Canada 13F-HR filing:, and Managing and. Therapeutics ( Organigramme ) Créer une alerte pour suivre le parcours de Simos.! `` MNPI '' ) Recharge ; in the Company 's previously announced $ million. Power to target multiple pathways of disease holdings are Worth over $ 1.26 million and represent 5.09 % shares! Concentre sur l'identification des microARN comme biomarqueurs de la Société se concentre sur l'identification des comme... Institute … '' We are pleased to add Jake and Simos to the Regulus board companies and former Vice of... ) Create an alert to follow the career of Simos Simeonidis sarissa capital regulus directors, or significant (! Vice Chairman of Cowen & Company $ 849,434,000 in managed 13F securities and a hedge fund in with! These 3 stocks: BCRX … '' We are pleased to add Jake and Simos to Regulus...
Premium Elite Glue,
Chipotle Carnitas Ingredients,
Wild Kratts: Creatures Of The Deep Sea,
Vayu Purana Pdf,
It Companies In Pretoria,
Types Of Jobs In Turkey For Foreigners,
Cupcake Cartoon Character,
Restaurants In Saratoga, Ca,
Herman Gulch Trail,
Hasta - Osrs,
Do The Granite Mountain Hotshots Still Exist,
Alwar Wala Kalakand,
Chicken Tikka 8 Pieces Calories,